Humanin: found in a brain that resisted Alzheimer’s, and still mostly an observation

Discovered by looking for whatever was protecting a brain that should have had Alzheimer’s and did not. Twenty years on it is one of the better-characterised mitochondrial-derived peptides and still has no human intervention data.

Where it came from and what it does

Established clinical use Humanin is a 21 to 24 amino acid peptide encoded within the mitochondrial genome — not the nucleus — making it a member of the same class as MOTS-c. It was identified in 2001 from a cDNA library made from the surviving brain region of an Alzheimer’s patient, screened for whatever was conferring resistance.

Animal-only or theoretical Its characterised activity is anti-apoptotic: it interferes with the Bax pathway and with several other death signals, and it binds receptor complexes on the cell surface. Downstream, the reported effects are neuroprotection, improved insulin sensitivity, and protection against ischaemic and oxidative injury — a broad cytoprotective profile rather than one specific action.

Circulating humanin declines with age, and studies in centenarians and their offspring have reported higher levels than in age-matched controls. That association is the source of most of the longevity interest.

What the association can and cannot support

Animal-only or theoretical There is no published randomised controlled trial of administering humanin to people, for any indication. Nor is there published human pharmacokinetics for the material in circulation, which is why the fact box above carries no rows for it.

The centenarian finding is worth reading carefully, because it is doing most of the persuasive work and it is the weakest kind of evidence for an intervention. Higher humanin in people who lived longer is consistent with humanin protecting them, and equally consistent with it being a readout of mitochondrial health that healthier people have more of. Administering a marker does not necessarily produce the state it marks — the same problem the MOTS-c page describes, and the reason both compounds sit at the same early stage despite twenty years of interest.

The app’s own drawbacks list leads with "very early clinical stage" and "limited human dosing data", which is the accurate summary and unusually restrained for a compound with this much enthusiasm behind it.

The practical position

There is no approved product and no reference standard. Identity and purity rest entirely with whoever made the vial, and this site names no vendor or testing service. It is also expensive and difficult to source, which the app notes.

The app records fasting glucose and HbA1c alongside cognitive self-assessment — reasonable given the insulin-sensitivity findings, and not a marker of whether the compound is doing anything. The HbA1c page covers why those two markers can disagree.

The reasonable position is real and interesting biology at a stage where nobody can say what administering it does to a person over months. Anyone using it is generating the only data that exists about it, and anyone with a metabolic or neurological condition should be raising it with the clinician managing that.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Humanin, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app’s own entry, and the first two items are the whole page: very early stage, limited human data.

• Very early clinical stage
• Limited human dosing data
• Optimal administration route still being determined
• Expensive and difficult to source
• Complex biology — systemic effects vary
• Not FDA approved

Questions people actually ask

Is there human trial data?

No published randomised trial for any indication, and no published human pharmacokinetics for the material people are using.

What does the centenarian finding show?

That people who lived a long time have higher circulating humanin than age-matched controls. That is consistent with it protecting them and equally consistent with it being a readout of mitochondrial health rather than a cause of it.

How does it relate to MOTS-c?

Same class — both encoded in mitochondrial DNA rather than the nucleus — and both at the same early evidence stage. Their reported activities differ: humanin is characterised as anti-apoptotic and cytoprotective, MOTS-c as metabolic.

Why is there no half-life in the fact box?

Because none has been published for the material in circulation, so the app holds none.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.